EA201792294A1 - Комбинированное лечение (варианты) с применением серибантумаба - Google Patents

Комбинированное лечение (варианты) с применением серибантумаба

Info

Publication number
EA201792294A1
EA201792294A1 EA201792294A EA201792294A EA201792294A1 EA 201792294 A1 EA201792294 A1 EA 201792294A1 EA 201792294 A EA201792294 A EA 201792294A EA 201792294 A EA201792294 A EA 201792294A EA 201792294 A1 EA201792294 A1 EA 201792294A1
Authority
EA
Eurasian Patent Office
Prior art keywords
seribantumab
options
combined treatment
cancer
methods
Prior art date
Application number
EA201792294A
Other languages
English (en)
Russian (ru)
Inventor
Бэмбэнг Адивиджайя
Акос Цибере
Рэйчел К. Неринг
Гэвин Макбит
Original Assignee
Мерримак Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерримак Фармасьютикалс, Инк. filed Critical Мерримак Фармасьютикалс, Инк.
Publication of EA201792294A1 publication Critical patent/EA201792294A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA201792294A 2015-04-17 2016-04-15 Комбинированное лечение (варианты) с применением серибантумаба EA201792294A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562149271P 2015-04-17 2015-04-17
PCT/US2016/027933 WO2016168730A1 (en) 2015-04-17 2016-04-15 Combination treatments with seribantumab

Publications (1)

Publication Number Publication Date
EA201792294A1 true EA201792294A1 (ru) 2018-03-30

Family

ID=55854801

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792294A EA201792294A1 (ru) 2015-04-17 2016-04-15 Комбинированное лечение (варианты) с применением серибантумаба

Country Status (13)

Country Link
US (1) US20160303232A1 (https=)
EP (1) EP3283068A1 (https=)
JP (1) JP2018513155A (https=)
KR (1) KR20170137886A (https=)
CN (1) CN107750165A (https=)
AU (1) AU2016248329A1 (https=)
CA (1) CA2983008A1 (https=)
EA (1) EA201792294A1 (https=)
HK (2) HK1248539A1 (https=)
IL (1) IL255092A0 (https=)
MA (1) MA45420A (https=)
SG (1) SG11201708491PA (https=)
WO (1) WO2016168730A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017161009A1 (en) * 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Dosage and administration of combination therapies comprising targeted antibodies uses and methods of treatment
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
CA3104868A1 (en) 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
CN115976196B (zh) * 2022-12-16 2024-12-06 深圳市人民医院 ErbB3作为肺动脉高压生物标志物和治疗靶点的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102580084B (zh) * 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
DK2500439T4 (da) 2005-06-20 2017-11-13 Advanced Cell Diagnostics Inc Kits og produkter til detektering af nukleinsyrer i individuelle celler og til identifikation af sjældne celler fra store heterogene cellepopulationer
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
EP2571992B1 (en) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
PH12013500064A1 (en) * 2010-07-09 2013-03-11 Exelixis Inc Combinations of kinase inhibitors for the treatment of cancer
WO2012103341A1 (en) 2011-01-27 2012-08-02 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid stage tumors using anti-erbb3 antibodies
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
MX2013010444A (es) * 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
AU2012275850A1 (en) 2011-06-30 2013-03-21 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel for treatment of gynecological cancers
AU2012294326A1 (en) 2011-08-10 2013-03-21 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
WO2013138371A1 (en) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
SG11201602291TA (en) * 2013-09-30 2016-04-28 Daiichi Sankyo Co Ltd Nucleic acid biomarker and use thereof
EP3087394A2 (en) * 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies

Also Published As

Publication number Publication date
US20160303232A1 (en) 2016-10-20
KR20170137886A (ko) 2017-12-13
HK1248539A1 (zh) 2018-10-19
CA2983008A1 (en) 2016-10-20
EP3283068A1 (en) 2018-02-21
HK1250626A1 (zh) 2019-01-11
WO2016168730A1 (en) 2016-10-20
JP2018513155A (ja) 2018-05-24
MA45420A (fr) 2019-05-01
SG11201708491PA (en) 2017-11-29
CN107750165A (zh) 2018-03-02
AU2016248329A1 (en) 2017-11-09
IL255092A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MX391720B (es) Terapia combinada para tratar cáncer.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201690905A1 (ru) Специфические антитела против cd38 для лечения злокачественных новообразований у человека
MX2016007351A (es) Terapia de combinacion para tratar cancer.
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
WO2015009726A3 (en) Medical uses of cd38 agonists
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
GEP20217317B (en) Combination therapy for the treatment of cancer
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MD20170025A2 (ro) Tratamente terapeutice pe bază de anamorelin
CY1122508T1 (el) Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου
BR112017019829A2 (pt) antagonista do receptor nk-3, para o tratamento terapêutico ou cosmético de gordura corporal em excesso
MX2020001727A (es) Terapia de combinacion.
EA202090260A1 (ru) Средства и способы для генотерапии aav у человека
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
EA201892631A1 (ru) Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака
BR112016023011A2 (pt) tratamento de câncer gástrico
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине